Skip to main content
SPRB
NASDAQ Life Sciences

Spruce Spins Out CRHX-101 Into Adrenyx, Targets Two Public Companies by H1 2027

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$46.55
Mkt Cap
$133.785M
52W Low
$38.06
52W High
$129
52W Position info
22% above low
Off High info
64% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

SPRB sits 22% above its 52-week low of $38.06.

Summary

Spruce is separating its CRHX-101 (formerly SPR-202) CAH program into Adrenyx Biosciences, a newly formed wholly-owned subsidiary, and intends to distribute Adrenyx shares pro rata to Spruce stockholders to create two independent public companies. The distribution is targeted for the first half of 2027 and is expected to be taxable to U.S. holders; it needs board approval, an effective SEC registration, and Nasdaq listing approval, but not a stockholder vote. Adrenyx already has financing lined up: a secured convertible note purchase agreement for up to $10.0 million, with $5.0 million issued at the November 6 initial closing, plus a planned private placement with up to $50 million funded by that investor. Spruce keeps TA-ERT for MPS IIIB as its lead asset, with a BLA submission planned for December 2026 and a potential U.S. launch next year. Samir Gharib will run Adrenyx while staying on as Spruce's President and CFO, so the split leaves Spruce a purer late-stage neurology story and gives the earlier-stage CAH antibody its own capital structure.

At the time of this announcement, SPRB was trading at $46.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $133.8M. The 52-week trading range was $38.06 to $129.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

SPRB - Latest Insights

SPRB
Aug 24, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $51.58
Real-time Price: $46.55 info
Change: -$5.03 (-10%) info
Market Cap: $133.785M info
SPRB
Aug 12, 2026, 9:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $46.41
Real-time Price: $46.55 info
Change: +$0.140 (+0.30%) info
Market Cap: $133.785M info
SPRB
Aug 12, 2026, 9:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $46.41
Real-time Price: $46.55 info
Change: +$0.140 (+0.30%) info
Market Cap: $133.785M info
SPRB
May 13, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $57.55
Real-time Price: $46.55 info
Change: -$11.00 (-19%) info
Market Cap: $133.785M info
SPRB
May 13, 2026, 8:13 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $56.67
Real-time Price: $46.55 info
Change: -$10.12 (-18%) info
Market Cap: $133.785M info